CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab ; volume:22 ; number:1 ; day:15 ; month:4 ; year:2022 ; pages:1-10 ; date:12.2022
BMC cancer ; 22, Heft 1 (15.4.2022), 1-10, 12.2022
- Urheber
-
Matsunaga, Tomoyuki
Saito, Hiroaki
Kuroda, Hirohiko
Osaki, Tomohiro
Takahashi, Sadamu
Iwamoto, Akemi
Fukumoto, Yoji
Taniguchi, Kenjiro
Fukuda, Kenji
Miyauchi, Wataru
Shishido, Yuji
Miyatani, Kozo
Fujiwara, Yoshiyuki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09482-8
- URN
-
urn:nbn:de:101:1-2022063020080121973421
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Matsunaga, Tomoyuki
- Saito, Hiroaki
- Kuroda, Hirohiko
- Osaki, Tomohiro
- Takahashi, Sadamu
- Iwamoto, Akemi
- Fukumoto, Yoji
- Taniguchi, Kenjiro
- Fukuda, Kenji
- Miyauchi, Wataru
- Shishido, Yuji
- Miyatani, Kozo
- Fujiwara, Yoshiyuki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
Natural History of Patients with Unresectable Cholangiocarcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
The effect of APN, hs-CRP and APN/hs-CRP in periodontitis with DAA
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
Natural History of Patients with Unresectable Cholangiocarcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
The effect of APN, hs-CRP and APN/hs-CRP in periodontitis with DAA
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
Natural History of Patients with Unresectable Cholangiocarcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer